An international team led by researchers from CEITEC Masaryk University has developed a computational method for designing entirely new antimicrobial peptides – short proteins capable of killing bacteria. Instead of relying on the lengthy process of searching for suitable molecules in nature, the researchers can now use molecular simulations to predict their properties and design new molecules with specific functions. The resulting peptides successfully eliminated bacteria resistant to conventional antibiotics and proved effective in preclinical mouse models. The findings introduce a new approach to developing future antibiotics as well as other biologically active peptides.According to the World Health Organization, antibiotic resistance is one of the greatest global health threats of our time. Every year, the number of bacteria resistant to available antibiotics continues to grow. At the same time, developing new drugs is a lengthy and costly process in which most candidate molecules ultimately fail.Researchers at CEITEC Masaryk University have therefore taken a different approach. Rather than searching randomly for antimicrobial compounds, they developed a method for designing them based on molecular design principles. Using molecular simulations, they analysed around 150 peptides in detail and identified the rules that govern the design of molecules capable of forming stable pores in bacterial membranes. These tiny openings disrupt the membrane barrier, causing bacteria to lose control of their internal environment and ultimately die. "We discovered how to arrange specific amino acids so that the resulting peptides form pores in bacterial membranes. This now allows us to generate an enormous number of peptide candidates and select those with the properties we are looking for," says <a target="_blank" rel="noopener noreferrer" href="https://www.ceitec.eu/prof-robert-vacha-ph-d/u27252">Robert Vácha</a> from CEITEC Masaryk University, who led the research.The researchers validated the most promising peptide designs experimentally. They confirmed their activity against a group of the most dangerous antibiotic-resistant bacteria. The best results were achieved against Acinetobacter baumannii, which the World Health Organization classifies as a priority drug-resistant pathogen. The team also demonstrated that their most successful peptide does not damage human red blood cells and shows no significant toxicity towards human cells. Its efficacy was further confirmed in two preclinical mouse models of bacterial infection.The significance of the study lies not only in identifying a new antibiotic candidate but, more importantly, in establishing a new design strategy. Based on their findings, the researchers developed a set of design principles and 52 sequence templates that can be used to design approximately 10 trillion molecules, providing other research teams with a framework for developing new membrane-disrupting peptides. The same principle that proved successful against bacteria could also be applied in the future to develop anticancer therapeutics, biosensors, or targeted drug delivery systems."Until now, researchers have mostly searched for biologically active molecules created by nature and only then investigated how they work. We reversed this process. First, we studied which molecular properties are required for a particular mechanism of action – in our case, the ability to stabilize membrane pores – and then used this knowledge to design entirely new peptides that make such pores. This approach could significantly accelerate the development of new medicines and help us keep pace with the growing challenge of antibiotic resistance," adds Robert Vácha, who has received ERC grants for his research.The study was carried out in collaboration with researchers from the University of Pennsylvania, the University of Groningen, Palacký University Olomouc, and the Institute of Microbiology of the Czech Academy of Sciences. The results were published in <a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41589-026-02269-z.epdf">Nature Chemical Biology</a>.<blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.nature.com/articles/s41589-026-02269-z#citeas">Computational design of antimicrobial peptide nanopores</a></h4>Rahul Deb, Marcelo D. T. Torres, Ivo Kabelka, Jan Přibyl, Kateřina Dvořáková Bendová, Edo Vreeker, Markéta Koběrská, Gabriela Balíková Novotná, Miloš Petřík, Giovanni Maglia, Cesar de la Fuente-Nunez &amp; Robert VáchaNat. Chem. Biol., 2026, 22, 1–12<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1038/s41589-026-02269-z">https://doi.org/10.1038/s41589-026-02269-z</a>&nbsp;<h6>Licenced under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstract</h4>Antibiotic resistance is a global health threat, driving the need for new molecules that kill bacteria via nontraditional mechanisms. Here, we present a computational de novo design strategy for α-helical peptides that self-assemble into large, stable and membrane-spanning nanopores with antimicrobial activity, including in vivo efficacy against drug-resistant pathogens. Molecular dynamics simulations guided the selection of sequences for transmembrane barrel-stave pore formation, which were validated by microscopy, electrophysiology and fluorescence assays. Using computational and experimental analyses, including negative design controls, we developed general design guidelines and 52 modular sequence templates with tunable antimicrobial, pore-forming properties. Mechanistic studies confirmed bacterial cytoplasmic membrane disruption via designed nanopore formation. A tuned lead peptide selectively killed drug-resistant ESKAPEE bacteria, including Acinetobacter baumannii, without harming human cells, and showed anti-infective efficacy in preclinical mouse infection models. The framework presented here enables the design of synthetic peptide nanopores for precision antimicrobials, anticancer agents, molecular sensors and delivery systems.

New Antibiotics Designed on a Computer: Scientists Develop a Blueprint for Building Molecules Against Drug-Resistant Bacteria 

A new study published in Nucleic Acids Research identifies short “start–stop” elements as highly effective regulators of protein synthesis in human cells. The study was co-led by Leoš Shivaya Valášek from IMIC CAS.<section><div><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/MBU_Nenapadne_start_stop_brany_reguluji_tvorbu_bilkovin_v_bunce_2_4d91bb348d.jpg" alt="MBU: Unassuming Start–Stop “Gates” Regulate Protein Production in Cells" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_MBU_Nenapadne_start_stop_brany_reguluji_tvorbu_bilkovin_v_bunce_2_4d91bb348d.jpg 245w," sizes="100vw" width="720" height="390"><section><div>An international team of scientists has described a&nbsp;previously overlooked mechanism that regulates the levels of important proteins in human cells. A new study published in Nucleic Acids Research reveals that short regulatory “start–stop“ elements act as highly effective speed-limiting gates of protein synthesis. Compared with previously known regulatory sequences, these elements were found to suppress protein production even more efficiently. At the same time, they help maintain low but stable levels of important proteins in cells, even under stress conditions. The study brought together scientists from the United States, the Czech Republic, Canada, and Sweden. Leoš Shivaya Valášek, Head of the Laboratory of Regulation of Gene Expression at the Institute of Microbiology of the Czech Academy of Sciences (IMIC CAS) was a&nbsp;co-author and one of the corresponding authors of the study.</div></section><section><div>During protein production, ribosomes read and translate information encoded in messenger RNA (mRNA) into amino acids, which are then assembled into a&nbsp;new protein. The researchers focused on an unusual sequence in which a&nbsp;start signal is immediately followed by a&nbsp;stop signal. As a&nbsp;result, the ribosome receives instructions to begin and terminate translation almost simultaneously. Although such an arrangement may appear illogical, it proved to be an important regulatory tool.Start–stop motifs are found in more than 1,400 human genes and are particularly common in genes that control cellular signaling pathways, the stress response, or the activity of transcription factors—that is, proteins that regulate the activity of other genes. These genes must be tightly controlled because even small changes in the amount of their protein products can have significant biological consequences.<h4>Resilience Under Stress</h4>The researchers tested the activity of this regulatory mechanism under stress conditions, including in the ATF4 gene, which plays a&nbsp;key role in the so-called integrated stress response. Cellular stress is typically associated with a&nbsp;global reduction in protein synthesis. The authors demonstrated that regulation mediated by start-stop elements is largely independent of the overall state of translation initiation and therefore remains effective even under cellular stress.<h4>A Stronger Brake Than Known Regulatory Elements</h4>The team compared start–stop sequences with similar regulatory regions known as uTranslons. Although both types of elements suppress protein synthesis, the start–stop sequences proved to be significantly more effective. Ribosomes remain associated with these motives for longer before proceeding to the main coding region of the gene.“Start-stop sequences are specialized regulatory elements that ensure increased ribosome retention, thereby allowing for fine-tuning translation,” says Leoš Valášek from IMIC CAS.The study expands our understanding of how cells fine-tune protein synthesis and may ultimately contribute to research on &nbsp;certain cancer and neurodegenerative disorders, and other diseases linked to disrupted protein production.</div></section><blockquote><h4>The original article</h4><h4><a target="_blank" rel="noopener noreferrer" href="https://academic.oup.com/nar/article/54/13/gkag627/8725953?login=false">Elongationless start–stop elements are stress-resilient translation gates that are more repressive than uTranslons</a></h4>Justin Rendleman, Solomon A Haizel, Shaohuan Wu, Laurelle Lee Young, Junjie Liu, Xinyi Ge, Huijing Zou, Mahabub Pasha Mohammad, Matthew Pressler, Shuvadeep Maity, Vladislava Hronová, Zhaofeng Gao, Anna Hermannová, Anna Smirnova, Amy Lei, Kristina Allgoewer, Daniel Sultanov, Will Edward Hinckley, Ziyue Cheng, Lauren Shelby, Tanubrata Dey, Krzysztof J Szkop, Ivan Topisirovic, Ola Larsson, Maria Hatzoglou, Leoš Shivaya Valášek, Christine VogelNucleic Acids Research (2026), Volume 54, Issue 13&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1093/nar/gkag627">https://doi.org/10.1093/nar/gkag627</a><h6>licenced under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/">CC-BY 4.0</a></h6></blockquote><h4>Abstract</h4>Start–stop elements are translation regulatory elements in 5′ untranslated regions (UTR) of eukaryotic transcripts, consisting of a start codon immediately followed by a stop codon. In contrast to canonical upstream Translons (uTranslons), they exclude elongation which creates unique properties. We conducted a comprehensive, carefully controlled comparison of human start–stop elements and uTranslons both at a genome-wide level and with targeted reporter assays. We found that start–stops and uTranslons were similar with respect to their presence in the 5′ UTRs of hundreds of genes, in particular transcription factors and signaling molecules, the low transcript levels of the corresponding genes, short RNA half-lives, and the negative effect on downstream translation. However, start–stop containing genes were translationally even more repressed than genes with uTranslons. Analysing the start–stop architecture and diverse ribosome footprinting datasets, we found evidence for a start–stop-specific mechanism that involves repeat cycling between initiation, termination, ribosome splitting, and 60S rejoining—a process possibly modulated by ASCC3 and eIF1. This cycling explained increased ribosome retention at start–stops and was—in contrast to ribosome retention at uTranslons—independent of the global initiation state. Finally, we showed that the start–stop element in human ATF4 augments the core regulatory model by controlling translation of the uTranslons.</div></section>

Unassuming Start–Stop “Gates” Regulate Protein Production in Cells

Why Biologics QC Is So Much Harder Than Small Molecule Pharma

Article

Scientists

Interview

Science and research

The Czech Academy of Sciences (CAS) was established by Act No. 283/1992 Coll. as the Czech successor of the former Czechoslovak Academy of Sciences. It is set up as a complex of 54 public research institutions.

Czech Academy of Sciences

Since its establishment in 2011, CEITEC has quickly developed into a cutting-edge infrastructure for research which performs highly alongside the best institutes in Europe. Among the main priorities of CEITEC are the promotion of a motivating and dynamic international scientific environment, the provision of state-of-the-art research infrastructure, and the policy of open communication and equal opportunities.

CEITEC

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Trajan Mitra Microsampling Devices - Specimen bag

The Specimen Bag Mitra format is perfect for those looking to create their own collection kits for remote sampling or maintain bulk devices for centralized sampling in clinical or field settings.

<h3>About</h3>The Specimen Bag Mitra format is perfect for those looking to create their own collection kits for remote sampling or maintain bulk devices for centralized sampling in clinical or field settings.Each Specimen Bag is sealed and includes a barcoded Mitra device with a unique identifier and desiccant. After collection, the device is placed back into the Specimen Bag to facilitate quick drying and protect the sample from external contamination.If you need logistics help, bioanalytical lab services, or kitting support, we can connect you with experienced organizations that specialize in microsampling.<h4>Build Your Own Kits or Sample Large Cohorts Remotely</h4>With this format you can collect many samples in the field and ship them back to the lab in bulk. You may prefer to insert them into your own all-in-one kit.<ul><li>10, 20, &amp; 30 µL volumes</li><li>Protective outer casing</li><li>Barcoding to manage chain of custody</li><li>Packed in specimen bag with desiccant for transport &amp; storage</li></ul><h3>Specifications</h3><div class="tabs__tab txt--light tabs__tab--active" id="tab_17218576460536_2"><ul><li>Indication for Use: A single-use, non-sterile device used as a specimen collector, and for the storage and transport of blood and other biological fluids for analytical and diagnostic analyses.&nbsp;</li><li>Sampler Tip Volume: 10, 20, or 30uL&nbsp;&nbsp;</li><li># of Samplers per Device: 2 or 4&nbsp;</li><li>Shelf Life: 18 months&nbsp;</li><li># Device per pack: 30/Pk</li><li>Pack content: Mitra Device, Specimen Bag with Desiccant, Sample ID Barcode, 1x IFU</li><li>Regulatory status: Mitra® devices are CE-IVD (IVDR) devices intended as a specimen collector, and for the storage and transport of blood and other biological fluids for analytical and diagnostic analyses. They are available as registered IVD Devices in the European Union and United Kingdom, Australia, Brazil, China, and Canada, as well as multiple Health Ministries worldwide. In the USA, Mitra devices are supplied as a research use only (RUO) product to assist in method development, other research-related and non-diagnostic activities. End-users and laboratories must validate the use of the Mitra devices for the particular diagnostic testing intended.</li></ul><h3>How to Use</h3><ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/IFUs/2023/Mitra%20Device%20Specimen%20Bag/VLBL-0125-Rrev00.pdf">Instructions for Use (RUO)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/IFUs/2023/Mitra%20Device%20Specimen%20Bag/VLBL-0125rev00.pdf">Instructions for Use (MD)</a></li></ul><h3>Resources</h3><ul style="list-style-type:disc;"><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_2022%20Mitra%20Collateral/Mitra%20Specification%20Sheet%20(3).pdf">Mitra Device Specification Sheet</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/User%20Guides/Mitra%20User%20Guide%20Extracting%20&amp;%20Processing%20Microsamples.pdf">User Guide | How to Extract &amp; Process Mitra Microsamples</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/Technical%20Briefs%20and%20Guidances/Long%20&amp;%20Short%20Term%20Storage%20of%20Mitra%20Samples_TG00010122.pdf">User Guide | How to Store Dried Mitra Microsamples</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/GenTegraRNA-NEO%20for%20Mitra%20devices%20USER%20GUIDE%2011.15.23.pdf">User Guide | How to Stabilizer RNA on Mitra Microsamples with GenTegraRNA-NEO™</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/frequently-asked-questions?hsLang=en">Frequently Asked Questions</a></li></ul><h3>Mitra devices deliver tremendous ease &amp; value to specimen collection!</h3></div>Mitra® Microsampling Devices offer a streamlined, flexible, and decentralized approach to biological specimen collection. Enjoy the benefits of easier trial recruitment, increased adherence / compliance, elimination of cold-chain shipping / storage &amp; reduced reliance on trained staff.<h4>The gold-standard in remote specimen collection</h4>Powered by VAMS® technology, the patented Mitra® Microsampling Device offers a streamlined, flexible, and decentralized approach to biological specimen collection, transport, and preparation. Use Mitra to facilitate sampling direct from animals, humans, or tubes to collect precise, reliable dried microsamples compatible with a wide variety of downstream applications as evidenced by the hundreds of published peer-reviewed manuscripts and the millions of devices that have been used in the field.<h4>Mitra: pioneering VAMS technology</h4>Trajan’s proprietary VAMS® Technology is at the heart of the Mitra device, featuring a sampler tip crafted from a porous, hydrophilic polymeric material. This 'precision sponge' rapidly and consistently absorbs a specific volume of biological fluid—simply by contacting the source. The fluid is then allowed to dry acting as a stabilizer for most analytes.Available in three tip sizes—10, 20, and 30 µL— and multiple formats, Mitra devices meet diverse end-user and analytical needs. Configurations include dual (2) or quad (4) samplers across various formats.&nbsp; Collect from 20 µL to 120 µL per device based on format selected. Our team of expert microsampling consultants is on hand to provide scientific support, helping you choose the optimal format and workflow for your specific applications.<ul><li>Reliable: Quantitative sampling with pipette-like precision (RSD ≤ 5%). VAMS eliminates traditional blood hematocrit biases and results in extremely low in-lab sample rejection rates. No glue used in assembly, no matrix interferences.</li><li>Versatile: Collect biological fluids—blood, plasma, urine, saliva, and even tears—efficiently from humans and animals (e.g., finger, arm, knee, tail, etc.) or containers. Manual to fully automated workflows are available.</li><li>User-Friendly: 99% sample acceptance rate validated by studies. VAMS tip acts as a fill indicator to confirm successful sampling. Outer housing protects against contamination and facilitates easy remote or home sampling.</li><li>Cost-Effective: Eliminate phlebotomy, couriers, and cold-chain shipping / storage requirements. Devices are compatible with standard automated liquid handling systems and available in various formats to suit different budgets.</li></ul><h4>Successful uses</h4>Have you seen the published, 3rd party literature of how others have successfully implemented Mitra devices?<ul><li>Preclinical</li><li>Clinical Trials / Research</li><li>Therapeutic Drug Monitoring</li><li>Omics</li><li>Biomonitoring</li><li>Toxicology</li><li>Hormones / Steroids</li><li>Biomarkers</li><li>Vitamins</li><li>Allergens</li><li>Population Screening</li><li>Infectious Diseases</li></ul>

Trajan Mitra Microsampling Devices - Microsample collection kit

The Microsample Collection Kit Mitra format streamlines the blood microsampling process, enabling both assisted and self-collection at home or in the field.

<h3>About</h3>The Microsample Collection Kit Mitra format streamlines the blood microsampling process, enabling both assisted and self-collection at home or in the field. Each kit is equipped with device, barcoding for secure chain of custody, easy-to-follow instructions, all necessary finger-prick sampling supplies, and a return-mailing envelope, all packaged for global distribution. Ideal for remote blood collection, these kits ensure that samples can be directly sent to accredited labs for precise analysis.For customization to meet the demands of large-scale projects or to optimize your workflows and logistics, please consult with our <a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/contact">Microsampling Consultants</a>. They will provide tailored recommendations to align with your project’s specific objectives.<h4>All-in-One Solution for Remote Specimen Collection</h4>Our Mitra devices can be packed in convenient kits with sterile components for safe sample collection. Kits can be shipped to your end-users.<ul><li>10, 20, &amp; 30 µL volumes</li><li>Protective outer casing</li><li>Barcoding to manage chain of custody</li><li>Packed in specimen bag with desiccant for transport &amp; storage</li><li>Contains devices &amp; supplies</li><li>Includes instructions for use &amp; return shipping envelope</li><li>Sized for easy global mailing</li></ul><h3>Specifications</h3><div class="tabs__tab txt--light tabs__tab--active" id="tab_1721774838869_2"><ul><li>Indication for Use: The Microsample Collection Kit is a single-use non-sterile procedure pack intended for the collection, storage and transport of capillary whole blood specimens of specified volume.</li><li>Sampler Tip Volume: 10, 20, or 30uL</li><li># of Samplers per Device: 2 or 4</li><li># Device per kit: 1/Pk</li><li>Pack content: 1x Mitra Device, 1x Specimen Bag with Desiccant, Sample ID Barcode, Lancet (x2 or x4), Gauze (x1 or x2), Bandage (x2 or x4), 1x Plastic Shipping Envelope, 1x IFU</li><li>Shelf Life: 18 months</li><li>Regulatory status: The Mitra Blood Sample Collection Kit is a procedure pack. The kits are available as registered Medical Device in the European Union and United Kingdom, Australia, Brazil, China, and Canada, as well as multiple Health Ministries worldwide. In the USA, procedure packs are supplied as a research use only (RUO) product to assist in method development, other research-related and non-diagnostic activities. End-users and laboratories must validate the use of the Mitra devices and Mitra Microsample collection kit for the particular diagnostic testing intended.</li></ul></div><h3>How to Use</h3><ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/IFUs/2023/Collection%20Kits/VLBL-0124-Rrev00.pdf">Instructions for Use (RUO)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/IFUs/2023/Collection%20Kits/VLBL-0124rev00.pdf">Instructions for Use (MD)</a></li></ul><h3>Resources</h3><ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_2022%20Mitra%20Collateral/Mitra%20Specification%20Sheet%20(3).pdf">Mitra Device Specification Sheet</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/Guidelines%20for%20Collecting%20Samples%20at%20Home-1.pdf">Guidelines for Collecting Samples at Home</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/Technical%20Briefs%20and%20Guidances/Long%20&amp;%20Short%20Term%20Storage%20of%20Mitra%20Samples_TG00010122.pdf">User Guide | How to Store Dried Mitra Microsamples</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/frequently-asked-questions">Frequently Asked Questions</a></li></ul><div class="tabs__tab txt--light tabs__tab--active" id="tab_1721774838869_4"><h3>Mitra devices deliver tremendous ease &amp; value to specimen collection!</h3>Mitra® Microsampling Devices offer a streamlined, flexible, and decentralized approach to biological specimen collection. Enjoy the benefits of easier trial recruitment, increased adherence / compliance, elimination of cold-chain shipping / storage &amp; reduced reliance on trained staff.<h4>The gold-standard in remote specimen collection</h4>Powered by VAMS® technology, the patented Mitra® Microsampling Device offers a streamlined, flexible, and decentralized approach to biological specimen collection, transport, and preparation. Use Mitra to facilitate sampling direct from animals, humans, or tubes to collect precise, reliable dried microsamples compatible with a wide variety of downstream applications as evidenced by the hundreds of published peer-reviewed manuscripts and the millions of devices that have been used in the field.<h4>Mitra: pioneering VAMS technology</h4>Trajan’s proprietary VAMS® Technology is at the heart of the Mitra device, featuring a sampler tip crafted from a porous, hydrophilic polymeric material. This 'precision sponge' rapidly and consistently absorbs a specific volume of biological fluid—simply by contacting the source. The fluid is then allowed to dry acting as a stabilizer for most analytes.Available in three tip sizes—10, 20, and 30 µL— and multiple formats, Mitra devices meet diverse end-user and analytical needs. Configurations include dual (2) or quad (4) samplers across various formats.&nbsp; Collect from 20 µL to 120 µL per device based on format selected. Our team of expert microsampling consultants is on hand to provide scientific support, helping you choose the optimal format and workflow for your specific applications.<ul><li>Reliable: Quantitative sampling with pipette-like precision (RSD ≤ 5%). VAMS eliminates traditional blood hematocrit biases and results in extremely low in-lab sample rejection rates. No glue used in assembly, no matrix interferences.</li><li>Versatile: Collect biological fluids—blood, plasma, urine, saliva, and even tears—efficiently from humans and animals (e.g., finger, arm, knee, tail, etc.) or containers. Manual to fully automated workflows are available.</li><li>User-Friendly: 99% sample acceptance rate validated by studies. VAMS tip acts as a fill indicator to confirm successful sampling. Outer housing protects against contamination and facilitates easy remote or home sampling.</li><li>Cost-Effective: Eliminate phlebotomy, couriers, and cold-chain shipping / storage requirements. Devices are compatible with standard automated liquid handling systems and available in various formats to suit different budgets.</li></ul><h4>Successful uses</h4>Have you seen the published, 3rd party literature of how others have successfully implemented Mitra devices?<ul><li>Preclinical</li><li>Clinical Trials / Research</li><li>Therapeutic Drug Monitoring</li><li>Omics</li><li>Biomonitoring</li><li>Toxicology</li><li>Hormones / Steroids</li><li>Biomarkers</li><li>Vitamins</li><li>Allergens</li><li>Population Screening</li><li>Infectious Diseases</li></ul></div>

Trajan Mitra Microsampling Devices - 96-autorack

The 96-Autorack™ format is designed for laboratories to efficiently batch and process Mitra microsamples using a standard 96-well format.

<h3>About</h3>The 96-Autorack™ format is designed for laboratories to efficiently batch and process Mitra microsamples using a standard 96-well format. Compatible with most 1mL &amp; 2mL collection plates and 96-channel pipettors &amp; liquid handling workstations, the 96-Autorack enhances lab productivity and integration. We provide two options: an empty 96-Autorack, perfect for accessioning microsamples from Mitra devices received from the field for building plates, extractions, and long-term storage; and prefilled 96-Autoracks with 96 Mitra samplers, ideal for method development and handling calibrators and QCs.<h4>Accession &amp; Process Multiple Mitra Samples at Once</h4>This high-throughput solution allows you to rapidly process Mitra microsamples for method development, plate building, extractions - or all of the above!<ul><li>Racks available empty or filled with 96 microsamplers (10, 20, &amp; 30 µL volumes)</li><li>Filled racks come with a 2mL deep well storage plate</li><li>Compatible with 96-channel pipettors &amp; liquid-handling workstations</li><li>Options with &amp; without barcoding</li></ul><h3>Specifications</h3><div class="tabs__tab txt--light tabs__tab--active" id="tab_17217760014256_2"><ul><li>Indication for Use: A single-use, non-sterile device used as a specimen collector, and for the storage and transport of blood and other biological fluids for analytical and diagnostic analyses.&nbsp;</li><li>Sampler Tip Volume: 10, 20, or 30uL&nbsp;&nbsp;</li><li># of Samplers per Device: 0 or 96&nbsp;</li><li># Device per pack: 1/Pk</li><li>Pack content: 1x 96-Autorack (empty or pre-filled), Sample ID Barcode, 1x Collection Plate, 1x IFU</li><li>Shelf Life: 18 months&nbsp;</li><li>Regulatory Status: Mitra® devices are CE-IVD (IVDR) devices intended as a specimen collector, and for the storage and transport of blood and other biological fluids for analytical and diagnostic analyses. They are available as registered IVD Devices in the European Union and United Kingdom, Australia, Brazil, China, and Canada, as well as multiple Health Ministries worldwide. In the USA, Mitra devices are supplied as a research use only (RUO) product to assist in method development, other research-related and non-diagnostic activities. End-users and laboratories must validate the use of the Mitra devices for the particular diagnostic testing intended.</li></ul><h3>How to Use</h3><ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Mitra%20IFUs/2024/VLBL-0098rev04.pdf">96-Autorack Instructions For Use (IVD)</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/IFUs/2023/96%20autorack/VLBL-0098-Rrev01.pdf">96-Autorack Instructions For Use (RUO)</a></li></ul><h3>Resources</h3><ul><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/User%20Guides/Mitra%20User%20Guide%20Extracting%20&amp;%20Processing%20Microsamples.pdf">User Guide | How to Extract &amp; Process Mitra Microsamples</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/NEOX_Content/Technical%20Briefs%20and%20Guidances/Long%20&amp;%20Short%20Term%20Storage%20of%20Mitra%20Samples_TG00010122.pdf">User Guide | How to Store Dried Mitra Microsamples</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/hubfs/GenTegraRNA-NEO%20for%20Mitra%20devices%20USER%20GUIDE%2011.15.23.pdf">User Guide | How to Stabilizer RNA on Mitra Microsamples with GenTegraRNA-NEO™</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://www.neoteryx.com/frequently-asked-questions?hsLang=en">Frequently Asked Questions</a></li></ul><h3>Mitra devices deliver tremendous ease &amp; value to specimen collection!</h3><div class="tabs__tab txt--light tabs__tab--active" id="tab_17217760014256_3"><div class="tabs__tab txt--light tabs__tab--active" id="tab_17217760014256_4">Mitra® Microsampling Devices offer a streamlined, flexible, and decentralized approach to biological specimen collection. Enjoy the benefits of easier trial recruitment, increased adherence / compliance, elimination of cold-chain shipping / storage &amp; reduced reliance on trained staff.<h4>The gold-standard in remote specimen collection</h4>Powered by VAMS® technology, the patented Mitra® Microsampling Device offers a streamlined, flexible, and decentralized approach to biological specimen collection, transport, and preparation. Use Mitra to facilitate sampling direct from animals, humans, or tubes to collect precise, reliable dried microsamples compatible with a wide variety of downstream applications as evidenced by the hundreds of published peer-reviewed manuscripts and the millions of devices that have been used in the field.<h4>Mitra: pioneering VAMS technology</h4>Trajan’s proprietary VAMS® Technology is at the heart of the Mitra device, featuring a sampler tip crafted from a porous, hydrophilic polymeric material. This 'precision sponge' rapidly and consistently absorbs a specific volume of biological fluid—simply by contacting the source. The fluid is then allowed to dry acting as a stabilizer for most analytes.Available in three tip sizes—10, 20, and 30 µL— and multiple formats, Mitra devices meet diverse end-user and analytical needs. Configurations include dual (2) or quad (4) samplers across various formats.&nbsp; Collect from 20 µL to 120 µL per device based on format selected. Our team of expert microsampling consultants is on hand to provide scientific support, helping you choose the optimal format and workflow for your specific applications.<ul><li>Reliable: Quantitative sampling with pipette-like precision (RSD ≤ 5%). VAMS eliminates traditional blood hematocrit biases and results in extremely low in-lab sample rejection rates. No glue used in assembly, no matrix interferences.</li><li>Versatile: Collect biological fluids—blood, plasma, urine, saliva, and even tears—efficiently from humans and animals (e.g., finger, arm, knee, tail, etc.) or containers. Manual to fully automated workflows are available.</li><li>User-Friendly: 99% sample acceptance rate validated by studies. VAMS tip acts as a fill indicator to confirm successful sampling. Outer housing protects against contamination and facilitates easy remote or home sampling.</li><li>Cost-Effective: Eliminate phlebotomy, couriers, and cold-chain shipping / storage requirements. Devices are compatible with standard automated liquid handling systems and available in various formats to suit different budgets.</li></ul><h4>Successful uses</h4>Have you seen the published, 3rd party literature of how others have successfully implemented Mitra devices?<ul><li>Preclinical</li><li>Clinical Trials / Research</li><li>Therapeutic Drug Monitoring</li><li>Omics</li><li>Biomonitoring</li><li>Toxicology</li><li>Hormones / Steroids</li><li>Biomarkers</li><li>Vitamins</li><li>Allergens</li><li>Population Screening</li><li>Infectious Diseases&nbsp;</li></ul></div></div></div>

Phenomenex Phree Phospholipid Removal Solutions

Phree Phospholipid Removal Solutions offer a fast effective way to remove proteins AND phospholipids from plasma samples without negatively affecting the recovery of your target analytes.

Phree Phospholipid Removal Solutions offer a fast effective way to remove proteins AND phospholipids from plasma samples without negatively affecting the recovery of your target analytes.<h5>One Quick Method, Three Big Advantages:</h5><ul><li>Remove Proteins</li><li>Eliminate Phosphopholipids,</li><li>No Method Development</li></ul><h5>A Simple 2-step Method</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Phree_Phospholipid_Removal_Solutions_A_Simple_2_Step_Method_c5ef7b809c.jpg" alt="Phenomenex: Phree Phospholipid Removal Solutions - A Simple 2-Step Method" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Phree_Phospholipid_Removal_Solutions_A_Simple_2_Step_Method_c5ef7b809c.jpg 245w," sizes="100vw" width="1378" height="548"><h5>How Phree Works</h5><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Phree_Phospholipid_Removal_Solutions_How_Phree_Works_eb279f0395.jpg" alt="Phenomenex: Phree Phospholipid Removal Solutions - How Phree Works" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Phree_Phospholipid_Removal_Solutions_How_Phree_Works_eb279f0395.jpg 232w," sizes="100vw" width="1107" height="745">

Products from category Sample preparation - page 1

Related content

Why Biologics QC Is So Much Harder Than Small Molecule Pharma

Unassuming Start–Stop “Gates” Regulate Protein Production in Cells

New Antibiotics Designed on a Computer: Scientists Develop a Blueprint for Building Molecules Against Drug-Resistant Bacteria